CPHI
CPHI | October 6-8, 2026 | Milan (ITA)
Mabion invites pharmaceutical and biotechnology companies to meet its experts during CPHI 2026. The industry trade show will take place at Fiera Milano from October 6-8. As one of the leading events in the global biopharma industry, CPHI will bring together companies, experts, innovators, and decision-makers from across the entire pharma supply chain to exchange knowledge, identify emerging opportunities, and build new international partnerships.
Meet Mabion at CPHI 2026!
Mabion is looking forward to engaging with biotechnology and pharmaceutical leaders seeking new models of collaboration in the development and manufacturing of biologic medicines.
Mabion will be represented at CPHI Milan 2026 by:
- Detlef Behrens, Chief Business Affairs Officer
- Joaquín Santos Benito, Chief Transformation Officer
- Ilona Hinz, Chief Financial Officer
- Judyta Suskiewicz, Director of Business Development
- Anna Czubatka-Bieńkowska, Director of Project Management Department
- Marta Bednarek, Director of Manufacturing Department
- Ewelina Zielińska-Rosik, Production Division Manager
- Jakub Knurek, Marketing Specialist
Our team focuses on innovative biologic drugs and addressing therapeutic areas of global demand. We are interested in projects that have the potential to improve access to advanced therapies across international markets. Complex biological programs increasingly require complementary expertise. Mabion is also open to establishing and participating in international partner consortia.
Open to co-development in orphan drugs
Mabion is particularly interested in co-development projects involving orphan drugs. During the CPHI, we invite all partners seeking flexible collaboration models to participate. Potential structures may include co-development programs, risk-sharing arrangements, asset-focused partnerships, licensing frameworks, and broader international alliances.
Through the integration of development, analytical, manufacturing, and regulatory expertise, Mabion aims to help partners reduce manage development risks and accelerate promising monoclonal antibody therapies for patient populations with limited treatment options.
Companies attending CPHI 2026 are invited to contact Mabion in advance to arrange a meeting with its experts. Contact us at bd@mabion.eu to schedule a meeting.